"With its low-THC and high-CBD products already on sale in Switzerland and France – and soon the UK – Swiss business CBD420® are keen to see clearer regulation around the supply of cannabis."
"To produce this strain, Duclos focused on further developing another component of cannabis: cannabidiol (CBD). So far, CBD isn't known to have psychoactive properties or side effects, but research has shown it can alleviate the effects of inflammation, depression and anxiety. It's also been seen to help patients suffering from multiple sclerosis, as well as various other ailments."
"People use cannabis products for health problems like Parkinson’s, epilepsy, and acne — but misinformation and out-of-date regulations are stopping most from benefitting."